Takeda Pharmaceutical (TAK) News
NYSE: TAKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.73+0.21 (+1.13%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TAK news summary
We found 28 recent headlines mentioning Takeda Pharmaceutical (TAK): 0 in the past week and 10 in the past 30 days, most often from Seeking Alpha, Nasdaq. For price context, TAK is up 1.13% at $18.73. The most recent story, "Takeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 Trial", was published by Nasdaq on Sep 30, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Takeda Pharmaceutical headlines
- Takeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 Trial(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK, 4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque…Nasdaq
- Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque…Nasdaq
- KROS Begins Dosing in Phase II Study With Rinvatercept in DMDKeros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.NasdaqKROS, REGN, TAK, PGEN
- Innovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock Down(RTTNews) - Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company focused on developing therapies across oncology and other major diseases, announced the expansion of the global Phase 3…Nasdaq
- Takeda Unveils $22.2 Mln CSR Collaborations Focused On Climate-Resilient Health; Stock Up(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK), a commercial-stage pharmaceutical company announced that it has granted $22.2 million to four new Corporate Social Responsibility (CSR) partners…Nasdaq
- Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.NasdaqBMY, AMGN, TAK
- Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaTAK, MS
- Best Value Stocks to Buy for September 14thSIG, TAK and TX made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 14th, 2026.NasdaqSIG, TX, TAK
- Takeda's Zasocitinib NDA Gets FDA Priority Review For Plaque Psoriasis; PDUFA Date Set For Q1' 27(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), on Monday reported that the U.S. Food and Drug Administration (FDA) has accepted Zasocitinib's New Drug Application (NDA) under priority…Nasdaq
- Best Income Stocks to Buy for September 14thTX, HPQ and TAK made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 14th, 2026.NasdaqHPQ, TX, TAK
- Takeda's Oveporexton Phase 3 Trials Meet All Endpoints; Data Published In NEJM(RTTNews) - Takeda (TAK) announced that Phase 3 data for oveporexton (ORZEYFUL) in adults with narcolepsy type 1 (NT1) have been published in the New England Journal of Medicine (NEJM).Nasdaq
- Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…Nasdaq
- Inventiva Names Chris Benecchi As COO Ahead Of Lanifibranor's Phase 3 Readout(RTTNews) - Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company, on Monday announced the appointment of Chris Benecchi as Chief Operating Officer (COO).NasdaqIVA, JNJ, TAK
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.Key PointsJ&J's portfolio primarily includes small biotech and medtech companies.NasdaqPTGX, JNJ, LAB, XNCR
- Takeda gains approval of rusfertide for polycythemia veraSeeking Alpha
- Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term ConcernSeeking Alpha
- Takeda Pharmaceutical Company Limited (TAK) Q1 2026 Earnings Call TranscriptSeeking Alpha
- Takeda Pharmaceutical Company Limited 2026 Q1 - Results - Earnings Call PresentationSeeking Alpha
- Takeda Pharmaceutical Company Limited (TAK) Shareholder/Analyst Call - SlideshowSeeking Alpha
- Takeda Pharmaceutical: The Downside Was ForecastableSeeking Alpha
- Takeda Pharmaceutical Company Limited (TAK) Q4 FY2025 Earnings Call TranscriptSeeking Alpha
- Takeda's Rich Pipeline Optionality Is Worth A 'Buy'Seeking Alpha
- Takeda Pharmaceutical Company Limited FY2025 Q4 - Results - Earnings Call PresentationSeeking Alpha
- Takeda Pharmaceutical Company Limited (TAK) Discusses Zasocitinib Phase III Psoriasis Data and Commercial Strategy TranscriptSeeking Alpha
- Takeda Pharmaceutical Company Limited (TAK) Discusses Zasocitinib Phase III Psoriasis Data and Commercial Strategy - SlideshowSeeking Alpha
- Takeda: 'Hold' Despite Performance In 2025-2026Seeking Alpha
- Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha
- Takeda Tests New Highs, But Struggles To Find Entyvio SuccessorSeeking Alpha